---
title: "Unity Biotechnology (UBX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/UBX.US.md"
symbol: "UBX.US"
name: "Unity Biotechnology"
industry: "Biotechnology"
---

# Unity Biotechnology (UBX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic ...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.13 | 93/603 | - | - | - |
| PB | -16.80 | 592/603 | 4.15 | 2.52 | 2.16 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/UBX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/UBX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/UBX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.